Pioneering Research to Develop Safe & Effective Immunomodulators to Stimulate the Soluble Tumor Microenvironment

Therapeutically targeting of soluble immune modulators in the tumor microenvironment (TME) has been shown to create ‘hot’ tumors, increasing T cell infiltration and better response rates to immune checkpoint blockade treatment.

As the whole immuno-oncology research community now pivots to engineering soluble factors and cytokines to transform the TME into an immunostimulatory state, acting as a complementary strategy to a suite of cancer immunotherapy approaches, the virtual Cytokine-Based Cancer Immunotherapies Summit has been established.

This is the ONLY industry dedicated meeting dedicated specifically to cytokine therapies. Join this exclusive community online to network and learn from the leading experts in pharma, biotech and academia, as we discuss how to successfully and safely deliver cytokine therapies to a plethora of cancer indications.

With 2 content packed digital days covering the latest results coming out of the clinic and addressing the shortfalls of these therapies, this is not one to miss!

World-Class Speaker Faculty Included:

Angus Sinclair

VP Immuno-Oncology

IGM Biosciences

Christian Klein - Speaker

Christian Klein

Head Oncology Programs, Department Head Cancer Immunotherapy Discovery 3

Roche Pharma Research & Early Development

Dario Neri - Speaker

Dario Neri

Co-CEO and CSO, Professor

Philogen & ETH Zürich

Geraldine O'Sullivan Coyne - resize

Geraldine O’Sullivan Coyne

Staff Clinician, Developmental Therapeutics Clinic

National Cancer Institute

Giovanni Abbadessa

Vice President, Head of Oncology Early Development


Proud to Partner With:

Companies Attending included:

Cytokine-Based Cancer Immunotherapies Summit - Companies attending Banner
Ruth Ganss, Harry Perkins Institute of Medical Research, University of Western Australia